Methylphenidate

1. 2026-10-19issueIssued info_card
2. 2026-09-24srcEvaluating Dopamine Reward Pathway in ADHD.
3. 2026-09-24srcMethylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
4. 2026-09-24srcEthylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.
5. 2026-09-24srcDrug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
6. 2026-09-24srcIncreased Plasma Concentrations of 6-oxo-Methylphenidate in CES1 G134E Carriers Following a Single Oral Dose of Methylphenidate.
7. 2026-09-24srcDirect comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.
8. 2026-09-24srcOverdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.
9. 2026-09-24srcIs Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?
10. 2026-09-24srcClinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo
11. 2026-09-24srcCatecholamine influences on dorsolateral prefrontal cortical networks.
12. 2026-09-24srcUnderstanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
13. 2026-09-24srcThe Pharmacokinetics and Pharmacogenomics of Psychostimulants.
14. 2026-09-24srcEffects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships.
15. 2026-09-24srcThe World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder.
16. 2026-09-24srcComparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis
17. 2026-09-24srcCentral nervous system stimulants in recreational and medical use.
18. 2026-09-24srcLong-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.
19. 2026-09-24srcMethylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system.
20. 2026-09-24srcComparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects.
21. 2026-09-24srcEthanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.
22. 2026-09-24srcThe impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios.
23. 2026-09-24srcPlasma concentrations of methylphenidate enantiomers in adults with ADHD and substance use disorder.
24. 2026-09-24srcPotential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.
25. 2026-09-24srcCardiovascular adverse events associated with norepinephrine-dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System.
26. 2026-09-24srcMethylphenidate and Psychotic Symptoms in Children and Adolescents: A Disproportionality Analysis on the WHO Safety Database (VigiBase).
27. 2026-09-24srcEchocardiographic Evaluation of the Effect of Long-Term Methylphenidate Use on Cardiovascular Functions.
28. 2026-09-24srcDifferentiating Between Methylphenidate Use and Misuse: Clinical Insights From University Students and Academic Staff.
29. 2026-09-24srcBrief psychosis induced by methylphenidate in a child with attention deficit disorder: a case report and literature review.
30. 2026-09-24srcA Rare Phenomenon, Recurrent Acute Dystonia after Withdrawal of Methylphenidate-immediate Release Form: A Pediatric Case with ADHD.
31. 2026-09-24srcA 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group.
32. 2026-09-24srcTherapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.
33. 2026-09-24srcEffect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.
34. 2026-09-24srcInfluence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.
35. 2026-09-24srcMethylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management.
36. 2026-09-24srcInfluence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate.
37. 2026-09-24srcMethylphenidate — PubChem Compound CID 4158
38. 2026-09-24srcAffinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters.
39. 2026-09-24srcMethylphenidate — Wikipedia
40. 2026-09-24srcMethylphenidate and tramadol drug interaction
41. 2026-09-04issueIssued emergency
42. 2026-09-04issueIssued info_card
43. 2026-09-04issueIssued notice
44. 2026-07-03proposaldependence · taper
45. 2026-06-04proposal43 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
46. 2026-06-04publicationPublication — backfill
47. 2026-05-03revisionRevision 1
48. 2026-05-03genGeneration — pipeline-v5pipeline-v5
49. 2026-05-03rungeneration run
50. 2026-04-24rungeneration run

The same entries, as forms: six forms.